NASDAQ | VICL: 2.43  +0.03
investors
Investors

Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting

05/23/2017


SAN DIEGO, May 23, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present clinical data on its completed Phase 1 trial of its novel antifungal, VL-2397, at the American Society of Microbiology (ASM) Microbe 2017 meeting, taking place June 1 – 5 in New Orleans. The Company will also present data from non-clinical VL-2397 studies. VL-2397 will be featured in an oral presentation and four poster presentations at the conference. Abstracts are available through the ASM Microbe Online Program Planner.

Oral Presentation

  • Sean Sullivan, Ph.D., Vical’s Senior Executive Director, Pharmaceutical Sciences, will present “Development of VL-2397 as a Novel Antifungal Drug Candidate to Treat Invasive Aspergillosis” in the conference’s New Agents Discovery Summary Session: Early New Antimicrobial Agents on June 3rd at 10:25 am. The slides presented by Dr. Sullivan will be made available on Vical’s website following the presentation.

Poster Presentations

  • Mammen P. "Anza" Mammen, Jr., M.D., Vical’s Vice President, Clinical Vaccines, will present the poster, “Phase 1 Safety and Pharmacokinetics Study of VL-2397, a Novel Antifungal Agent,” on the safety and pharmacokinetics data from the VL-2397 Phase 1 study. This poster session begins on June 2nd at 12:45pm.
  • Laura Kovanda from Astellas Pharma and the University of Liverpool, will present the poster, “Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single and Multiple Dose Phase 1 Study,” on a population pharmacokinetic analysis from the VL-2397 Phase 1 study. This poster session begins on June 2nd at 12:45pm.
  • Dr. Sean Sullivan will present the poster, “Characterization of Potential Drug Interactions and Off-Target Activities of VL-2397, a Novel Antifungal Agent against Invasive Aspergillosis,” on the limited potential drug interactions of VL-2397 demonstrated in vitro. This poster session begins on June 3rd at 12:15pm.
  • Nathan Wiederhold, Pharm.D., from the University of Texas Health Science Center San Antonio, will present the poster, “The Novel Antifungal VL-2397 Demonstrates Efficacy in an In Vivo Model of Invasive Candidiasis Caused by Wild-Type and Multi-Drug Resistant Candida glabrata,” reviewing an NIH-sponsored in vivo study that investigated the effect of VL‑2397 to treat wild-type and drug-resistant Candida glabrata. This poster session begins on June 3rd at 12:15pm.

Vical plans to conduct a Phase 2 efficacy study to evaluate VL-2397 for the treatment of invasive aspergillosis and is working with clinical experts and the FDA towards this objective. The FDA has granted Vical Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designations to VL-2397 for the treatment of invasive aspergillosis. Under the QIDP designation Vical has been able to interact intensively with the FDA on the design of the Phase 2 trial and in exploring an expedited development pathway for VL‑2397.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include anticipated developments in clinical programs, including the plans, timing of initiation, and enrollment for clinical trials. Risks and uncertainties include whether Vical or others will continue development of VL-2397; whether Vical  will be able to obtain regulatory allowances or guidance necessary to proceed with proposed clinical trials or implement anticipated clinical trial designs; whether on-going or planned clinical trials will be initiated or completed on the timelines Vical currently expects, whether any product candidates will be shown to be safe and efficacious in clinical trials; whether Vical will have access to sufficient capital to fund its planned development activities; whether Vical will seek or gain approval to market any product candidates; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact:         
Andrew Hopkins
(858) 646-1127
Website:  www.vical.com

Primary Logo

Source: Vical Incorporated

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.